Advertisement

Advertisement

2025 ASCO Annual Meeting

Skin Cancer
Immunotherapy

Dual Immunotherapy May Improve Progression-Free Survival in Advanced Squamous Cell Carcinoma

The combination of avelumab and cetuximab may improve progression-free survival in patients with advanced cutaneous squamous cell carcinoma compared with avelumab alone, according to recent findings p...

Prostate Cancer
Genomics/Genetics

Biomarkers May Shed Light on Treatment Options for High-Risk Prostate Cancer

Researchers may have uncovered factors contributing to poor outcomes among patients with prostate cancer, according to recent findings presented by Dall’Era et al at the 2025 ASCO Annual Meeting (Abst...

Multiple Myeloma

Potential New Standard of Care Emerges in Multiple Myeloma

A new four-drug combination appears to be effective and safe in patients with newly diagnosed multiple myeloma, according to data from the ADVANCE clinical trial conducted by investigators at Sylveste...

Asaf Maoz, MD, on Li-Fraumeni Syndrome: Multimodality Screening Program 

Asaf Maoz, MD, of Dana-Farber Cancer Institute/Mass General Brigham/Harvard Medical School, reviews the results of a prospective study of whole-body magnetic resonance imaging as part of cancer screen...

pancreatic cancer

Asaf Maoz, MD, on Pancreatic Surveillance Eligibility Criteria

Asaf Maoz, MD, of Dana-Farber Cancer Institute/Mass General Brigham/Harvard Medical School, discusses the sensitivity of age and family history criteria for determining eligibility for pancreatic canc...

lung cancer

Martin Reck, MD, PhD, on Postsurgical MRD, Genomic Mutations, and Outcomes in Resectable NSCLC: AEGEAN Trial

Martin Reck, MD, PhD, of LungenClinic Grosshansdorf, Germany, discusses data from the phase III AEGEAN trial that studied perioperative durvalumab and neoadjuvant chemotherapy. Patients who were MRD-p...

lung cancer

Rami Manochakian, MD, FASCO, on Tarlatamab vs Chemotherapy for Second-Line Treatment of SCLC: Expert Point of View

Rami Manochakian, MD, FASCO, of Mayo Clinic Florida, offers his thoughts on findings from the primary analysis of the phase III DeLLphi-304 trial, which compared tarlatamab-dlle, a bispecific T-cell e...

colorectal cancer

Frank A. Sinicrope, MD, on Adjuvant Treatment Strategies for Stage III dMMR Colon Cancer

Frank A. Sinicrope, MD, of Mayo Clinic Rochester, reviews findings from the randomized Alliance A021502/ATOMIC trial, which studied standard chemotherapy alone or combined with atezolizumab as adjuvan...

Solid Tumors
Supportive Care
Issues in Oncology

Scholastic Performance Among Adolescents and Young Adults With Cancer

Adolescent and young adult (AYA) patients with cancer may need support for scholastic performance, according to new findings presented by Fisher et al at the 2025 ASCO Annual Meeting (Abstract 11053)....

Hematologic Malignancies
Supportive Care
Issues in Oncology

New Application May Help Caregivers of Patients Undergoing Bone Marrow Transplant

A novel application could help to improve the quality of life among caregivers of patients undergoing bone marrow transplant, according to recent findings presented by Jacobs et al at the 2025 ASCO An...

gynecologic cancers

Alicia Latham, MD, MS, on Using ctDNA to Detect Endometrial Cancer

Alicia Latham, MD, MS, of Memorial Sloan Kettering Cancer Center, discusses the feasibility of using Pap-derived ctDNA for the detection of sporadic and Lynch syndrome–associated endometrial cancer (A...

Issues in Oncology
Solid Tumors

Meta-Analysis Reveals How ICIs May Impact Solid Organ Transplant Responses

In the results of a meta-analysis of solid organ transplant recipients who have received immune checkpoint inhibitors as cancer treatment, the study authors concluded that immunotherapy may be “high r...

Breast Cancer

Menopause Medication May Help to Prevent Invasive Breast Cancer, Study Finds

A drug already approved by the FDA to treat menopause symptoms may also help to prevent invasive breast cancer, according to recent findings from a clinical trial led by Northwestern Medicine. The res...

Lung Cancer

HER3-Targeted Antibody-Drug Conjugate for Treatment-Resistant Solid Tumors

Results from an international clinical trial demonstrated that DB-1310, a new antibody-drug conjugate, is showing early signs of effectiveness in patients with advanced solid tumors that have not resp...

Breast Cancer

Trastuzumab Deruxtecan/Pertuzumab Leads to Improved PFS for HER2-Positive Breast Cancer

Results from the phase III DESTINY-Breast09 clinical trial found that the combination of fam-trastuzumab deruxtecan-nxki (T-DXd) with pertuzumab may delay cancer growth for longer than the current sta...

breast cancer

Stephen K.L. Chia, MD, FRCPC, on Advanced HER2-Negative and ER-Positive Breast Cancer: SERD and AKT Inhibitor

Stephen K.L. Chia, MD, FRCPC, of BC Cancer Agency, reviews data from the phase III CCTG/BCT MA.40/FINER trial of fulvestrant and ipatasertib for advanced HER2-negative, ER-positive breast cancer follo...

lung cancer

David R. Spigel, MD, FASCO, on NSCLC Treatment Planning: Role of 14-Gene Molecular Assay

David R. Spigel, MD, FASCO, Chief Scientific Officer of Sarah Cannon Research Institute, reviews data on the role of a 14-gene molecular assay in selecting patients with stage IA–IIA non–small cell lu...

genomics/genetics

Angela R. Bradbury, MD, on Genetic Testing Approach in Patients With Metastatic Cancers

Angela R. Bradbury, MD, of the University of Pennsylvania, presents findings from the eREACH trial—a randomized study of an eHEALTH delivery alternative for cancer genetic testing for hereditary predi...

pancreatic cancer

Sameek Roychowdhury, MD, PhD, on Telemedicine in Clinical Trials

Sameek Roychowdhury, MD, PhD, of the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at The Ohio State University Wexner Medical Center, discusses a recently opened telemedici...

cns cancers

Manmeet Singh Ahluwalia, MD, MBA, FASCO, on Liquid Biopsy in Glioblastoma

Manmeet Singh Ahluwalia, MD, MBA, FASCO, of Miami Cancer Institute, Baptist Health South Florida, discusses the ongoing LIBERATE trial, which is evaluating safety and technical efficacy of transcrania...

breast cancer

Karen Eubanks Jackson on Receiving the 2025 ASCO Patient Advocate Award

Karen Eubanks Jackson, Founder and Chief Executive Officer of Sisters Network Inc. and recipient of the 2025 ASCO Patient Advocate Award, discusses her 30-year-long effort to support patients with bre...

colorectal cancer

Elena Elez, MD, PhD, on Updated Survival Data From the BREAKWATER Trial

Elena Elez, MD, PhD, of Vall d’Hebron Institute of Oncology, presents updated overall survival data as well as progression-free survival data from the BREAKWATER trial of the first-line use of encoraf...

breast cancer

Sara M. Tolaney, MD, MPH, FASCO, on PD-L1–Positive Advanced TNBC: First-Line Doublet Comparison

Sara M. Tolaney, MD, MPH, FASCO, of Dana-Farber Cancer Institute and Harvard Medical School, discusses findings from the phase III ASCENT-04/KEYNOTE-D19 study, which compared sacituzumab govitecan-hzi...

genomics/genetics

Arelis Esther Martir-Negron, MD, on Prevalence of BRCA Variants in Hispanic Residents of South Florida

South Florida has a unique demographic, characterized by a large Hispanic population with ancestries from the Caribbean and Central and South America. Arelis Esther Martir-Negron, MD, of Miami Cancer ...

breast cancer

Mafalda Oliveira, MD, PhD, on How Does Hyperglycemia Affect Treatment of Advanced Breast Cancer?

Mafalda Oliveira, MD, PhD, of Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology, discusses findings on the incidence and management of hyperglycemia in a subset of patients wit...

lung cancer

David Allen Barbie, MD, on Clinical and Molecular Features of Participants in the ADRIATIC Trial

David Allen Barbie, MD, of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute, reviews specific clinical and molecular features of early progressors and long-term progression-free s...

Breast Cancer

ASCO 2025: Switching to Camizestrant After Detection of an ESR1 Mutation Improves Progression-Free Survival for Some Patients With Advanced Breast Cancer

Switching to treatment with camizestrant if an ESR1 mutation is detected during first-line treatment can help slow cancer growth for patients with hormone receptor (HR)-positive, HER2-negative advance...

Issues in Oncology
Colorectal Cancer

Impact of Empirical Dietary Inflammatory Pattern on Survival Outcomes in Patients With Stage III Colon Cancer

Greater intake of a proinflammatory dietary pattern may be linked to worse overall survival in patients with stage III colon cancer who have undergone curative-intent resection. Sara K. Char, MD, a cl...

Gastroesophageal Cancer

ASCO 2025: Perioperative Durvalumab Boosts FLOT Chemotherapy Benefit for Patients With Gastric Cancers

Results from an international phase III clinical trial found that treating patients with stage II, III, and IVA resectable gastric cancer and gastroesophageal junction (GEJ) cancer with perioperative ...

prostate cancer

Andrew J. Armstrong, MD, MS, on ARCHES: 5-Year Overall Survival Follow-up

Andrew J. Armstrong, MD, MS, of Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University School of Medicine, discusses the 5-year overall survival analysis of the ARCHES trial, ...

Clifford A. Hudis, MD, FASCO, FACP, on ASCO Guidelines Assistant

Clifford A. Hudis, MD, FASCO, FACP, Chief Executive Officer of ASCO, discusses ASCO Guidelines Assistant, an AI-based collaboration between ASCO and Google Cloud which draws from ASCO’s evidence-based...

colorectal cancer

Heinz-Josef Lenz, MD, on MSI-H/dMMR Metastatic Colorectal Cancer: Expanded Analyses From CheckMate 8HW

Heinz-Josef Lenz, MD, of the University of Southern California Norris Comprehensive Cancer Center, reviews analyses from the CheckMate 8HW trial, which evaluated nivolumab plus ipilimumab vs chemother...

Colorectal Cancer

ASCO 2025: Structured Exercise Program Improves Survival, Outcomes in Some Patients With Colon Cancer

A phase III study has found that a 3-year structured exercise program initiated soon after completion of adjuvant chemotherapy improves disease-free and overall survival, as well as patient-reported p...

leukemia

Mazyar Shadman, MD, PhD, on Doublet for Treatment-Naive CLL/SLL

Mazyar Shadman, MD, PhD, of Fred Hutchinson Cancer Center and the University of Washington, presents results from arm D of the SEQUOIA trial, which evaluated the combination of zanubrutinib and veneto...

gastrointestinal cancer

Yelena Y. Janjigian, MD, on Gastric/GEJ Cancer: Immunotherapy Plus FLOT

Yelena Y. Janjigian, MD, of Memorial Sloan Kettering Cancer Center, presents event-free survival data from the phase III MATTERHORN trial of the PD-L1 inhibitor durvalumab plus FLOT (fluorouracil, leu...

lung cancer

Raffaele Califano, MD, on EGFR-Mutant Advanced NSCLC: MARIPOSA-2

Raffaele Califano, MD, of the Christie NHS Foundation Trust and the University of Manchester, discusses outcomes by osimertinib resistance mechanisms in MARIPOSA-2, a study that evaluated the efficacy...

Head and Neck Cancer

ASCO 2025: Adding Nivolumab to Adjuvant Chemoradiotherapy Reduces Risk of Recurrence in Locally Advanced Head and Neck Cancer

Adding nivolumab to chemoradiotherapy after surgery can decrease the chance of recurrence in patients with locally advanced head and neck squamous cell carcinoma, according to findings from the intern...

Colorectal Cancer

ASCO 2025: Adding Atezolizumab to Adjuvant Chemotherapy Improves Disease-Free Survival in dMMR Colon Cancer

Results from the international phase III ATOMIC study demonstrated that patients with deficient mismatch repair (dMMR) colon cancer who receive atezolizumab in addition to adjuvant chemotherapy experi...

breast cancer

Nicholas C. Turner, MD, PhD, on Treating Emergent ESR1 Mutations in Advanced Breast Cancer

Nicholas C. Turner, MD, PhD, of the Royal Marsden Hospital, presents findings from the phase III, double-blind ctDNA-guided SERENA-6 trial, which evaluated the combination of camizestrant plus a CDK4/...

head and neck cancer

Stuart J. Wong, MD, on Adjuvant Regimen in Resected HNSCC

Stuart J. Wong, MD, of the Medical College of Wisconsin and Plenary discussant, reviews findings from the phase III NIVOPOSTOP randomized trial, which investigated the adjuvant use of nivolumab added ...

hematologic malignancies

Andrew Kuykendall, MD, on Hepcidin Mimetic for Polycythemia Vera

Andrew Kuykendall, MD, of Moffitt Cancer Center, discusses findings from the phase III VERIFY trial, which compared the efficacy of rusfertide vs placebo in patients with polycythemia vera who continu...

colorectal cancer

Christopher M. Booth, MD, on a Structured Exercise Program for Patients With Colon Cancer

Christopher M. Booth, MD, of Queen’s University, reviews findings from the randomized phase III Canadian Cancer Trials Group (CCTG) CO.21 (CHALLENGE) trial, which evaluated the impact of a structured ...

leukemia

Constantine Si Lun Tam, MD, FRACP, FRCPA, MBBS, on CLL/SLL: First-Line Zanubrutinib Monotherapy in Patients With del(17p)

Constantine Si Lun Tam, MD, FRACP, FRCPA, MBBS, of Alfred Hospital and Monash University, reviews results from the 5-year follow-up of arm C of the SEQUOIA trial of treatment-naive patients with chron...

breast cancer

Nicholas C. Turner, MD, PhD, on INAVO120: Final Overall Survival Analysis

Nicholas C. Turner, MD, PhD, of the Royal Marsden Hospital, presents final overall survival data from the INAVO120 trial of inavolisib/placebo plus palbociclib and fulvestrant in patients with PIK3CA-...

breast cancer

Giuseppe Curigliano, MD, PhD, on Patient-Reported Outcomes From EMBER-3

Giuseppe Curigliano, MD, PhD, of Istituto Europeo di Oncologia, IRCCS, University of Milano, discusses patient-reported outcomes from the phase III EMBER-3 trial, which investigated treatment with iml...

leukemia

William G. Wierda, MD, PhD, on Lisocabtagene Maraleucel in Relapsed/Refractory CLL: TRANSCEND CLL 004 

William G. Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses two abstracts on lisocabtagene maraleucel (liso-cel) in relapsed/refractory (R/R) chronic lymphocytic leukem...

leukemia

William G. Wierda, MD, PhD, on Fixed-Duration Ibrutinib and Venetoclax in First-Line CLL

William G. Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, reviews the final analysis of phase II CAPTIVATE study demonstrating the long-term efficacy and safety of ibrutinib pl...

Breast Cancer

Sacituzumab Govitecan and Pembrolizumab Improve Disease Control in Advanced PD-L1–Positive Triple-Negative Breast Cancer

Results from an international phase III clinical trial show that treatment with sacituzumab govitecan-hziy and pembrolizumab helps patients with unresectable, locally advanced or metastatic PD-L1–posi...

Gastroesophageal Cancer

Trastuzumab Deruxtecan Improves Survival Outcomes in Patients With HER2-Positive Gastric/GEJ Cancer in Second-Line Setting

The international phase III DESTINY-Gastric04 clinical trial found that second-line treatment with fam-trastuzumab deruxtecan-nxki can help people with advanced HER2-positive gastric cancers that have...

Lung Cancer

Molecular Assay Identifies Patients With Early NSCLC Likely to Benefit From Adjuvant Chemotherapy

Results from an international clinical trial show that a 14-gene molecular assay can help identify patients with early-stage nonsquamous non–small cell lung cancer (NSCLC) who could benefit from adjuv...

Advertisement

Advertisement




Advertisement